MIMs and its partners are building PandemIA: An explainable Artificial Intelligence platform to personalize COVID-19 vaccination and treatment
Montréal, April 9, 2020 - Montreal-based My Intelligent Machines (MIMs), a leader in artificial intelligence applied to life sciences, along with academic and industry partners, is currently developing PandemIA : An explainable Artificial Intelligence platform to personalize COVID-19 vaccination and treatment. Discussions are ongoing with major partners to join MIMs in this initiative including CARTaGENE, Hexoskin and the Infectious Diseases and Immunity in Global Health (IDIGH) program of the Research Institute of the McGill University Health Centre (RI-MUHC).
PandemIA monitors genomic, clinical and geodynamic data and delivers real-time indicators to public health organizations. These indicators will allow the identification of subgroups of the population most at risk of developing deadly forms of the COVID-19 and those associated with efficacy and toxicity issues of vaccines and treatments. The anticipated impact of this partnership is to better control the pandemic, improve the health of Canadians and accelerate the economic rebound.
“48% of patients in intensive care units due to severe forms of COVID-19 are within the active 20 to 63 age group1. PandemIA will help public health organizations identify the most “at risk” people in the general population, in order to optimize essential services during a pandemic and the future economic rebound while protecting the health of active workers” says Dr. Jenna, CEO of MIMs.
A Privacy-by-design collaborative AI project
“Data security and privacy have been among the limiting factors in the adoption of evidence-based approaches to help health organizations use AI in taking proactive decisions for personalized care of patients in a pandemic context” says Dr. Diallo, Chief scientist of MIMs, based on his 10 years experience in epidemiological surveillance initiatives and OECD and WHO committees on AI associated with healthcare.
Dr. Camus, CTO/COO of MIMs continues: “ We built the MIMs platform to meet the highest quality, privacy and security standards. Our AI makes it possible to help prioritize the profiles most at risk by taking into account several biological, clinical and epidemiological factors in a transparent and explicit manner.”
A Canadian partnership that will maximize the efficiency of pandemic vaccines.
“We are lucky in Quebec and Canada to have CARTaGENE, the Quebec population cohort, a pioneer in biobanking with its 43,000 participants from 40 to 69 years of age, engaged in accelerating research.” says Alexandra Obadia, CEO of CARTaGENE.
Moreover, the partnership will leverage the groundbreaking wearable technologies developed by Hexoskin “Hexoskin smart shirts capture high resolution respiratory data, in addition to cardiac and activity data to better understand the clinical status of these patients” explains Pierre-Alexandre Fournier, CEO of Hexoskin.
PandemIA also benefits from the expertise of the IDIGH in the implementation of clinical tests for pathogen detection and management in the Canadian health systems. “We will join the efforts to generate valuable insights on the most effective COVID-19 vaccine, while considering consumer safety our top priority, to fortify the front line of the battle.” says Dr. Ndao, Director of the National Reference Centre for Parasitology (NRCP), Associate Professor, Dep. of Medicine of McGill University and (IDIGH) Program of (RI-MUHC).
My Intelligent Machines (MIMs) is a Montreal-based company founded in 2016 by Sarah Jenna (CEO), Abdoulaye Baniré Diallo (CSO) and Mickael Camus (CTO / COO). MIMs platform helps Bio-Pharma and Agritech companies use bioinformatics, systems biology and machine learning to leverage their massive OMIC, clinical/phenotypical and environmental data to maximize R&D and production. Dr. Diallo is a renowned specialist in viral genome classification and clinical virology involved in eight collaborative projects on viral surveillance and epidemiology carried out in Canada and in Africa.
CARTaGENE is a public research platform of the CHU Sainte-Justine created to accelerate health research. CARTaGENE consists of both biological samples and health data from 43,000 Québec residents between 40 to 69 years of age at baseline. Originally founded by Dr. Claude Laberge and Prof. Bartha Maria Knoppers, CARTaGENE is now under the direction and scientific direction of Alexandra Obadia (CEO), Dr. Philippe Broët (CHU Sainte-Justine), Dr. Guillaume Lettre (Montreal Heart Institute) and Dr. Simon Gravel (McGill University).
The RI-MUHC, located in Montreal, is the research arm of the McGill University Health Centre that has a mandate to focus on complex care within its community. The IDIGH Program integrates research on infectious diseases, immunity and global health at the RI-MUHC into work groups with a strong translational focus. A distinguishing feature of the program are cross-disciplinary research teams encompassing basic biomedical, clinical and health outcomes research that jointly work on novel ways to improve patient well-being and population health in targeted diseases.
Founded in 2006 in Montreal, Hexoskin is a growing private company, leader in non-invasive sensors, software, data science & AI services. The company provides solutions and services directly to customers & researchers; and through B2B contracts in pharmaceutical, academic, healthcare, security, defence, first responders, aerospace public & private organizations.